PMID- 21212677
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20151119
IS  - 1421-9913 (Electronic)
IS  - 0014-3022 (Linking)
VI  - 65
IP  - 2
DP  - 2011
TI  - Adherence to disease-modifying therapies in spanish patients with relapsing 
      multiple sclerosis: two-year interim results of the global adherence project.
PG  - 59-67
LID - 10.1159/000323216 [doi]
AB  - The post-marketing international Global Adherence Project investigated adherence 
      to disease-modifying therapy for relapsing-remitting multiple sclerosis. We 
      report adherence data from the first 2 years in the Spanish subset of patients (n 
      = 254 at baseline). The overall adherence rate was 85.4%. Patients taking 
      intramuscular (IM) interferon-beta (IFNbeta)-1a were significantly more adherent 
      (96.4%) compared with patients taking subcutaneous (SC) IFNbeta-1a 22 mug (79.1%; p = 
      0.0064), SC IFNbeta-1a 44 mug (79.6%; p = 0.0064) and glatiramer acetate (82.7%; p = 
      0.0184). At year 1 (n = 142), the overall adherence rate was 86.6%. Patients on 
      IM IFNbeta-1a were significantly more adherent than patients on SC IFNbeta-1a 22 mug 
      (93.9 vs. 66.7%; p = 0.0251). At year 2 (n = 131), the overall adherence rate was 
      82% (87.5% for IM IFNbeta-1a, 80.0% for SC IFNbeta-1a 22 mug, 77.8% for SC IFNbeta-1a 44 
      mug, 85.2% for IFNbeta-1b, and 80.0% for glatiramer acetate). In conclusion, 
      adherence remained high among all disease-modifying therapies over the first 2 
      years of the study and was significantly higher for IM IFNbeta-1a, at visit 1, 
      compared with SC IFNbeta-1a.
CI  - Copyright (c) 2011 S. Karger AG, Basel.
FAU - Arroyo, E
AU  - Arroyo E
AD  - Biogen Idec Iberia SL, Madrid, Spain. estefania.arroyo@biogenidec.com
FAU - Grau, C
AU  - Grau C
FAU - Ramo-Tello, C
AU  - Ramo-Tello C
FAU - Parra, J
AU  - Parra J
FAU - Sanchez-Solino, O
AU  - Sanchez-Solino O
CN  - GAP Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110104
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 0 (Immunologic Factors)
RN  - 0 (Peptides)
RN  - 5M691HL4BO (Glatiramer Acetate)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Disease Progression
MH  - Female
MH  - Glatiramer Acetate
MH  - Humans
MH  - Immunologic Factors/*administration & dosage/therapeutic use
MH  - Injections, Intramuscular
MH  - Injections, Subcutaneous
MH  - Interferon-beta/*administration & dosage/therapeutic use
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy
MH  - Peptides
MH  - Retrospective Studies
MH  - Spain
FIR - Ramo, C
IR  - Ramo C
FIR - Grau, L
IR  - Grau L
FIR - Roquer, J
IR  - Roquer J
FIR - Munteis, E
IR  - Munteis E
FIR - Martinez, E
IR  - Martinez E
FIR - Ramio i Torrento, L L
IR  - Ramio i Torrento LL
FIR - Merchan, M
IR  - Merchan M
FIR - Brieva, L
IR  - Brieva L
FIR - Lacruz, F
IR  - Lacruz F
FIR - Bujanda, M
IR  - Bujanda M
FIR - de Castro, P
IR  - de Castro P
FIR - Marzo, E
IR  - Marzo E
FIR - Hernandez, M A
IR  - Hernandez MA
FIR - Gonzalez, M
IR  - Gonzalez M
FIR - de Andres, C
IR  - de Andres C
FIR - Martinez, M
IR  - Martinez M
FIR - Izquierdo, G
IR  - Izquierdo G
FIR - Sanchez, F
IR  - Sanchez F
FIR - Aguera, E
IR  - Aguera E
FIR - Sanchez, V
IR  - Sanchez V
FIR - Guerrero, M
IR  - Guerrero M
FIR - Arnal, C
IR  - Arnal C
FIR - Bowakin, D
IR  - Bowakin D
FIR - Renedo, F
IR  - Renedo F
FIR - Cacho, J
IR  - Cacho J
FIR - Yusta, A
IR  - Yusta A
FIR - Perez, A
IR  - Perez A
FIR - Belenguer, A
IR  - Belenguer A
EDAT- 2011/01/08 06:00
MHDA- 2011/06/15 06:00
CRDT- 2011/01/08 06:00
PHST- 2010/04/02 00:00 [received]
PHST- 2010/11/29 00:00 [accepted]
PHST- 2011/01/08 06:00 [entrez]
PHST- 2011/01/08 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 000323216 [pii]
AID - 10.1159/000323216 [doi]
PST - ppublish
SO  - Eur Neurol. 2011;65(2):59-67. doi: 10.1159/000323216. Epub 2011 Jan 4.